Literature DB >> 8354905

Comparative inhibitory effects of various nucleoside and nonnucleoside analogues on replication of influenza virus types A and B in vitro and in ovo.

M Hosoya1, S Shigeta, T Ishii, H Suzuki, E De Clercq.   

Abstract

Six nucleoside analogues, two sulfated polysaccharides, and four protease inhibitors were evaluated in vitro as inhibitors of influenza virus replication. Four guanosine analogues (mizoribine, ribavirin, pyrazofurin, and 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide), the sulfated polysaccharide dextran sulfate (molecular weight 500,000), and two protease inhibitors (camostat mesilate and nafamostat mesilate) were inhibitory to the replication of strains of influenza virus types A and B at concentrations down to 0.3 micrograms/mL. Of these seven compounds, ribavirin, camostat mesilate, and nafamostat mesilate were efficacious in both reducing the virus titer and increasing the survival rate of influenza virus-infected chick embryos. For camostat mesilate, the ED50 (required to improve the survival rate of influenza virus-infected chick embryos by 50%) was 0.80 micrograms/g, and its selectivity index, based on the ratio of the 50% toxic dose (required to reduce the viability of chick embryos by 50%) to ED50, was 280. Camostat mesilate deserves further exploration for its potential in the treatment of influenza virus infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8354905     DOI: 10.1093/infdis/168.3.641

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Effective ribavirin concentration in hamster brains for antiviral chemotherapy for subacute sclerosing panencephalitis.

Authors:  T Ishii; M Hosoya; S Mori; S Shigeta; H Suzuki
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

2.  Evaluation of anti-influenza effects of camostat in mice infected with non-adapted human influenza viruses.

Authors:  M G Lee; K H Kim; K Y Park; J S Kim
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

3.  Treatment with ribavirin and interferon-alpha reduces interferon-gamma expression in patients with chronic hepatitis C.

Authors:  A Bergamini; F Bolacchi; M Cepparulo; F Demin; I Uccella; B Bongiovanni; D Ombres; F Angelico; A Liuti; M Hurtova; S Francioso; C Carvelli; G Cerasari; M Angelico; G Rocchi
Journal:  Clin Exp Immunol       Date:  2001-03       Impact factor: 4.330

4.  Occurrence of flavonoids and nucleosides in agricultural soils.

Authors:  D A Phillips; C M Joseph; P R Hirsch
Journal:  Appl Environ Microbiol       Date:  1997-11       Impact factor: 4.792

Review 5.  Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19.

Authors:  Mark Laws; Yasmin M Surani; Md Mahbub Hasan; Yiyuan Chen; Peiqin Jin; Taha Al-Adhami; Madiha Chowdhury; Aqeel Imran; Ioannis Psaltis; Shirin Jamshidi; Kazi S Nahar; Khondaker Miraz Rahman
Journal:  Curr Med Chem       Date:  2021       Impact factor: 4.530

6.  Ribavirin increases mitogen- and antigen-induced expression of CD40L on CD4+ T cells in vivo.

Authors:  A Bergamini; M Cepparulo; F Bolacchi; A Araco; G Tisone; D Ombres; G Rocchi; M Angelico
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

7.  Efficacy and Safety of a Quadruple Regimen Compared with Triple Regimens in Patients with Mycophenolic Acid-Related Gastrointestinal Complications After Renal Transplantation: A Short-Term Single-Center Study.

Authors:  Zhiguo Peng; Wanhua Xian; Huaibin Sun; Engang Li; Lina Geng; Jun Tian
Journal:  Ann Transplant       Date:  2020-02-28       Impact factor: 1.530

8.  Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus.

Authors:  Masayuki Saijo; Shigeru Morikawa; Shuetsu Fukushi; Tetsuya Mizutani; Hideki Hasegawa; Noriyo Nagata; Naoko Iwata; Ichiro Kurane
Journal:  Antiviral Res       Date:  2005-02-19       Impact factor: 5.970

Review 9.  Recent progress in anti-influenza chemotherapy.

Authors:  S Shigeta
Journal:  Drugs R D       Date:  1999-09

10.  In Vitro and in Vivo Antiviral Activity of Mizoribine Against Foot-And-Mouth Disease Virus.

Authors:  Shi-Fang Li; Mei-Jiao Gong; Yue-Feng Sun; Jun-Jun Shao; Yong-Guang Zhang; Hui-Yun Chang
Journal:  Molecules       Date:  2019-05-03       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.